IOVA Q1 2024 Earnings — Iovance Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

IOVAIovance Biotherapeutics, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$715,000

Gross Profit

-$7M-915.5% margin

Operating Income

-$118M-16464.6% margin

Net Income

-$113M-15800.8% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+48.3%

Cash Flow

Operating Cash Flow

-$122M

Free Cash Flow

-$126M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$870M

Total Liabilities

$190M

Stockholders' Equity

$680M

Cash & Equivalents

$134M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$715,000	$0	—
Gross Profit	-$7M	$0	—
Operating Income	-$118M	-$111M	-6.2%
Net Income	-$113M	-$107M	-5.2%

Geographic Segments

Non-US

$700,000100%